The tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of the matrix metalloproteinases (MMPs), enzymes that play central roles in the degradation of extracellular matrix components. The balance between MMPs and TIMPs is important in the maintenance of tissues, and its disruption affects tissue homoeostasis. Four related TIMPs (TIMP-1 to TIMP-4) can each form a complex with MMPs in a 1:1 stoichiometry with high affinity, but their inhibitory activities towards different MMPs are not particularly selective. The three-dimensional structures of TIMP-MMP complexes reveal that TIMPs have an extended ridge structure that slots into the active site of MMPs. Mutation of three separate residues in the ridge, at positions 2, 4 and 68 in the amino acid sequence of the N-terminal inhibitory domain of TIMP-1 (N-TIMP-1), separately and in combination has produced N-TIMP-1 variants with higher binding affinity and specificity for individual MMPs. TIMP-3 is unique in that it inhibits not only MMPs, but also several ADAM (a disintegrin and metalloproteinase) and ADAMTS (ADAM with thrombospondin motifs) metalloproteinases. Inhibition of the latter groups of metalloproteinases, as exemplified with ADAMTS-4 (aggrecanase 1), requires additional structural elements in TIMP-3 that have not yet been identified. Knowledge of the structural basis of the inhibitory action of TIMPs will facilitate the design of selective TIMP variants for investigating the biological roles of specific MMPs and for developing therapeutic interventions for MMP-associated diseases.
Introduction
The extracellular matrix (ECM) in multicellular organisms holds cells and tissues together, and creates appropriate cellular environments by forming organized molecular scaffolds. The spatial and temporal turnover of ECM molecules is therefore an integral part of many biological processes, such as embryo development, organ morphogenesis, tissue remodelling and repair, cell differentiation, migration, growth and apoptosis [1, 2] . Various types of proteinases are involved in the catabolism of the ECM, but the major ECM-degrading enzymes are the matrix metalloproteinases (MMPs) or matrixins [3, 4] . More than 30 matrixins have been found, including those in hydra [5] , sea urchins [6] and plants [7] . In humans, 23 matrixin genes have been identified. Recent studies have also indicated that members of the ADAM (a disintegrin and metalloproteinases) and ADAMTS (ADAM with thrombospondin motifs) families participate in ECM processing and degradation [8] . The activities of these metalloproteinases must be highly regulated under physiological conditions. Indeed, the expression levels of many matrixins in normal steady-state tissues are very low or negligible, but they are transcriptionally regulated by growth factors, hormones, inflammatory cytokines, cell-cell and cell-matrix interactions, and cellular transformations [1, 2] , suggesting that they function upon demand. The activities of matrixins are also controlled through zymogen activation and inhibition by endogenous protein inhibitors. The disruption of this balance may result in diseases, such as arthritis, atheroma, cancer, nephritis, encephalomyelitis, fibrosis, etc. [9] .
The major endogenous inhibitors of matrixins are the tissue inhibitors of metalloproteinases (TIMPs) and a plasma glycoprotein, ␣ 2 -macroglobulin (␣ 2 M), and related molecules. Human ␣ 2 M consists of four identical subunits of molecular mass 180 kDa, and it inhibits most endopeptidases, regardless of their substrate specificity and catalytic mechanism, by the unique 'trap' mechanism. This mechanism was first proposed by Alan Barrett and Phyllis Starkey in 1973 [10] , based on their observations that most endopeptidases form a complex with ␣ 2 M, but that this interaction is triggered by cleavage of ␣ 2 M subunits, and that inhibition of the bound proteinase is observed with a large protein substrate, but not with a small peptidic substrate. These results indicate that ␣ 2 M does not block the active site of the proteinase, but it blocks enzymic action on a large protein substrate by steric hindrance. Matrixins bind reasonably rapidly to ␣ 2 M. Collagenase 1 (MMP-1) preferentially binds to ␣ 2 M when equal concentrations of ␣ 2 M and TIMP-1 are present in solution [11] . However, ␣ 2 M is considered to inhibit matrixins in the fluid phase, whereas TIMPs regulate them in the tissue.
General biochemical properties of TIMPs
The vertebrate TIMPs comprise a family of four members (TIMP-1 to TIMP-4). Each TIMP consists of 184-195 amino acids, and the four TIMPs show approx. 40% sequence identity [12] . The expression of these TIMPs in different tissues and cell types is also controlled in order to maintain balanced ECM catabolism during tissue remodelling under physiological conditions [13, 14] . Vertebrate TIMPs have 12 conserved cysteine residues and contain Nterminal and C-terminal domains each stabilized by three disulphide bonds, whereas invertebrate TIMPs have different structural features, although they are related to vertebrate TIMPs. Two TIMPs in Caenorhabditis elegans lack the Cterminal domain, and Drosophila TIMP lacks two cysteines corresponding to Cys 13 and Cys 120 of human TIMP-1, but has two additional cysteines in its Cterminal domain. Drosophila TIMP probably has two disulphide bonds in the N-terminal domain and four disulphide bonds in the C-terminal domain [12] .
Vertebrate TIMPs interact with MMPs in a 1:1 stoichiometry with high affinity. They exhibit some differences in specificity. Thus TIMP-1 inhibits most MMPs with K i values of around 0.1-3.0 nM [15] , but is a poor inhibitor of MMP-14 (membrane-type 1-MMP) [16] and MMP-19 [17] . TIMPs-2, -3 and -4 inhibit all MMPs tested so far, but TIMP-2 and TIMP-4 bind MMP-2 very tightly [18] [19] [20] . Hutton et al. [18] reported that the overall dissociation constant of the complex between TIMP-2 and MMP-2 was 0.6 fM, indicating essentially irreversible complex formation. This tight binding is due largely to the interaction between the C-terminal domain of TIMP-2 and the C-terminal haemopexin domain of MMP-2 [18, 21] . TIMP-3 inhibits MMP-1 and MMP-2 with K i s in the low nanomolar range, but its affinity for MMP-3 is lower [22] . TIMP-3, on the other hand, is unique in that that it inhibits several members of the ADAM and ADAMTS families. Target proteases include ADAM-10 [23] , ADAM-12 [24] , ADAM-17/tumour necrosis factor ␣ (TNF␣)-converting enzyme [25] , ADAMTS-1 [26] , ADAMTS-4 [22, 27] and ADAMTS-5 [22] , whereas ADAM-8 and ADAM-9 are not inhibited by TIMPs [28] . However, the structural bases of these differential inhibitory features among TIMPs are not well understood.
In addition to interacting with active MMPs, some TIMPs bind to the zymogens of MMPs (proMMPs). ProMMP-2 (gelatinase A) binds to TIMP-2, -3 or -4 through interactions between its C-terminal haemopexin domain and the C-terminal domain of the TIMP [20, [29] [30] [31] . Also, proMMP-9 (progelatinase B) binds to TIMP-1 or TIMP-3 via their C-terminal domains [31, 32] . These binary complexes inhibit mature MMPs, as the N-terminal inhibitory domain of the TIMP is exposed to the solvent. Ternary complex formation between proMMP-2, TIMP-2 and MMP-14 (membrane-type 1-MMP) is essential for the activation of proMMP-2 by MMP-14 on the cell surface. As discussed in Chapters 1, 6 and 21 in this volume, the TIMP-2-bound MMP-14 acts as a 'receptor' for proMMP-2, and the adjacent MMP-14, free of TIMP-2, acts as an 'activator'.
Mechanism of inhibition of MMPs by TIMPs
TIMP-1 was first isolated as a collagenase inhibitor from the culture medium of connective tissues [33, 34] . Later it was shown to inhibit other MMPs [35] . The first three-dimensional structure of a TIMP was the NMR structure of the N-terminal domain of TIMP-2 (N-TIMP-2), determined by Williamson et al. [36] . It revealed a five-stranded ␤-barrel with a Greek key topology and two ␣-helices, a structure known as an OB fold, but the study did not identify the site that interacts with MMPs. Proteins with an OB fold include a group of
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oligonucleotide-and oligosaccharide-binding (OB) proteins, such as staphylococcal nuclease, bacterial enterotoxins and some tRNA synthases [37] .
To investigate the potential interaction site of TIMPs for MMPs, we used the differential proteolytic susceptibility of TIMP-1 and the TIMP-1-MMP-3 complex [38] . The study suggested that the region near Val 69 and Cys 70 of TIMP-1, which is disulphide-bonded to Cys 1 , is involved in the interaction with MMPs. This proposal was based on the observation that neutrophil elastase cleaved the Val 69 -Cys 70 bond of TIMP-1 and that this single proteolytic event inactivated the inhibitor, but TIMP-1 was protected from inactivation by elastase when it was complexed with MMP-3 (stromelysin 1). The inhibitory activity of TIMP-1 was recovered from the elastase-treated complex after dissociation. The NMR solution structure of N-TIMP-2 shows that the region around the Cys 1 -Cys 70 disulphide bond, comprising Glu 67 -Ser-Val-Cys 70 and Cys 1 -Thr-Cys-Val 4 (residue numbering from TIMP-1), forms a contiguous ridge, suggesting that this region might represent the reactive site of the inhibitor. We also conducted an extensive mutational study of N-TIMP-1 [39] . One N-TIMP-1 mutant with a substitution of Ala for Thr 2 (T2A) exhibited strikingly differential effects on three MMPs: compared with the wild type, the affinities for MMP-1, MMP-2 and MMP-3 decreased by approx. 1600-, 30-and 250-fold respectively (Table 1 ). Mutations at other sites changed TIMP-1 activity, but the changes were relatively modest and, unlike the T2A mutant, the proportional change was similar for all three MMPs [39] . Mutation of either Cys 1 or Cys 70 , which are disulphide-bonded in native TIMP-1, had large disruptive effects on TIMP-1 inhibitory activity [39, 40] . Again these results suggest that the reactive site of TIMPs is located in or close to the ridge region.
The mechanism of MMP inhibition by TIMP was elucidated by the crystal structure of the complex of TIMP-1 and the catalytic domain of MMP-3 lacking the C-terminal haemopexin domain ( [41] ; see Figure 1a ), and subsequently the structure of the TIMP-2-MMP-14 complex [42] , both determined by Bode and colleagues. The structure of the TIMP-1-MMP-3 complex showed that TIMP-1 is a 'wedge-shaped' molecule, and that the ridge described above was inserted into the active site of the enzyme. In this complex, approx. 75% of the protein-protein contacts in TIMP-1 are from the N-terminal stretch of Cys 1 to Val 4 and the loop region of Met 66 to Val 69 that are linked by the Cys 1 -Cys 70 disulphide bond. Residues 1-4 of TIMP-1 bind to the enzyme in an analogous way as the P1-P1Ј-P2Ј-P3Ј residues of a peptide substrate (proteolytic cleavage occurs between P1 and P1Ј), and the side chain of Thr 2 extends into the large S1Ј specificity pocket (the substrate-binding pocket that accepts the P1Ј residue of the substrate) of MMP-3. Ser 68 and Val 69 occupy part of the active site (S2 and S3 subsites respectively), but they are in a nearly opposite orientation to that of a bound peptide substrate (Figures 1a and 1b) . The active-site Zn 2+ of the enzyme is bidentately chelated by the ␣-amino acid and the carbonyl group of the Nterminal Cys 1 . The OH group of Thr 2 interacts with Glu 202 of MMP-3 and displaces a water molecule from the active site that is essential for peptide hydrolysis. Figure 1(c) highlights the residues of TIMP-1 within 4 Å of MMP-3 to identify the reactive ridge.
Altered specificity of TIMP-1 due to mutagenesis of residue 2
The S1Ј specificity pockets of the various MMPs differ in size, and therefore substrate specificity is greatly influenced by the nature of this pocket [43] . TIMPs have Thr or Ser in position 2. We therefore speculated that TIMP variants with a larger side chain at this position may be more selective for different MMPs. We used N-TIMP-1 rather than the full-length TIMP-1, as it is readily folded from the inclusion bodies of Escherichia coli when overexpressed. The His 2 mutant did not fold in vitro, but other mutants were compatible with the native fold, as judged by near-UV CD spectra. The position 2 variants were tested against MMP-1, -2 and -3 prototypes of collagenase, gelatinase and represents a loss of 33-55% of the free energy of interaction. The crystal structure of the MMP-3-TIMP-1 complex indicated that approx. 1300 Å 2 of the accessible surface of each molecule is buried upon formation of the complex [41] , but Thr 2 occupies only 8% (108/1300 Å 2 ) of the area of the TIMP-1-MMP interaction site, even assuming that it is totally exposed in the free inhibitor and completely buried upon binding to an MMP. This disproportionately large effect on binding indicates that Thr 2 in TIMP-1 is a 'hot spot' in the MMP-TIMP interaction interface. The C-terminal domain of TIMP-1 makes a few contacts with the protease, but contributes less than 10% of the free energy of binding. Negatively charged side chains at position 2 are unfavourable for all three MMPs as compared with the Asn 2 and Gln 2 mutants. Ser, Val and Met are well tolerated, and the best inhibitors for MMP-1, MMP-2 and MMP-3 were the Val 2 , Met 2 and Ser 2 variants respectively. The reasonably high affinity of the Arg 2 mutant for MMP-2 and MMP-3 is surprising, since peptides with Arg in the P1Ј position are extremely poor substrates for these enzymes [45] . The unfavourable interaction of the Arg 2 mutant with MMP-1 may be due to the presence of Arg 195 in the S1Ј pocket of MMP-1, whereas Leu is found in this position in MMP-2 and MMP-3.
Although mutation of residue 2 of N-TIMP-1 significantly influences its affinity for three MMPs tested, it is striking that there is a very poor correlation between the effects of a particular amino acid in the P1Ј position of a peptide substrate and those of the same residue in position 2 of N-TIMP-1 on MMP inhibition. For example, the best N-TIMP-1 mutant for inhibiting MMP-1 is the Val 2 variant, but an octapeptide with Val 2 in the P1Ј position is a poor substrate. Similarly, Ser and Arg in the P1Ј position in the substrate are not well tolerated by MMP-2 or MMP-3 [45] . Figure 2 shows an example of very poor correlation when ϪlogK i for position 2 mutants of N-TIMP-1 is plotted against log(k cat /K m ) for octapeptides with the same substitutions in the P1Ј position. Such a discrepancy may be due to a greater loss of conformational entropy associated with the peptide-substrate-MMP interaction compared with the TIMP-MMP interaction. Because the reactive ridges of TIMPs are rigid due to two disulphide bonds (Cys 1 -Cys 70 and Cys 3 -Cys 99 ), the conserved proline at position 5 and the interaction of Cys 1 with the active-site Zn 2+ , the orientation of residue 2 of TIMP-1 may be greatly influenced, and thus it dictates specificity.
Mutation of residues 4 and 68 of TIMP-1 and combined mutagenesis
The crystal structure of the TIMP-1-MMP-3 complex indicates that the side chain of Val 4 of TIMP-1 interacts with the S3Ј subsite of the enzyme, and that Ser 68 interacts with the S2 subsite. Four mutants were designed for each position to test their influence in specificity. Compared with position 2 mutations, the changes observed are moderate [46] (Table 1 ). V4S and V4K mutants are more selective for MMP-2 than the wild type. Mutations of Ser 68 have greater effects on MMP binding. The S68Y mutant inhibits MMP-3 much more strongly than MMP-1 or -2. Double and triple mutants with combinations of some selective single-site mutants show further selectivity.
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The double mutant T2L/V4S maintains excellent affinity for MMP-2, but shows decreased reactivity with MMP-1 and MMP-3 by 350-fold and 30-fold respectively; it does however retain low nanomolar K i values for MMP-2 and MMP-3. The triple mutant T2S/V4A/S68A has the highest inhibitory activity for MMP-3 among all mutants characterized so far, with a K i value of 50 pM. It also has an improved affinity for MMP-2 compared with the wild type, but binding to MMP-1 is reduced. The properties of the multi-site mutants suggest that the effects of some combinations of substitutions are essentially additive, indicating that interactions with the S1Ј, S3Ј and S2 subsites of the MMP contribute independently to the stability of the TIMP-MMP complex. However, some mutants exhibit effects that are not additive. For example, the T2L/V4S/S68Y mutant has a Ͼ100-fold higher affinity for MMP-3 than expected, although the K i values for MMP-1 and MMP-2 are in good agreement with predicted values. The T2S/N4A/S68Y mutant is a 60-fold better inhibitor of MMP-1 and a 68-fold better inhibitor of MMP-2 than predicted values based on additivity. These results indicate interactive effects among the sites in these multisite mutants. This suggests that the local structure of substrate-binding sites differs significantly among the three MMPs, in spite of the fact that the overall polypeptide folds of different MMPs are very similar (see Chapter 1).
Mutational studies of N-TIMP-3
TIMPs are specific inhibitors of matrixins. Exceptions to this are the inhibition of several members of the ADAM and ADAMTS metalloproteinases by TIMP-3, and the inhibition of ADAM-10 by TIMP-1 [23] . TIMP-3 also blocks the shedding of TNF␣ receptor 1 [47, 48] , Fas [48] , TNF-related apoptosis- and for Xaa in the substrate Gly-Pro-Gln-Gly↓Xaa-AlaGly-Gln (where ↓ is the scissile bond) [45] .
inducing ligand receptor 1 [48] , L-selectin [49] , interleukin-6 receptor [50] , syndecans-1 and -4 [51] , and CD163 [52] . Because these processes are not inhibited by other TIMPs, the enzymes responsible for these activities are postulated to be membrane-bound metalloproteinases belonging to the ADAM family. The primary structures of the metalloproteinase domains of ADAMs and ADAMTSs are related, but they have little sequence similarity with MMPs except around the catalytic zinc-binding motif, HEXXHXXGXXH [8] . The apparent K i values of N-TIMP-3 as an inhibitor of ADAM-17 (TNF␣-converting enzyme) [53] and ADAMTS-4 and -5 [22] are subnanomolar. ADAMTS-4 and -5 are also called aggrecanase 1 and 2 respectively, because of their ability to cleave the Glu 373 -Ala 374 bond of the core protein of aggrecan. More recently, ADAMTS-1 was also shown to have aggrecanase activity. N-TIMP-3, but not TIMP-1 or TIMP-2, inhibits interleukin-1-induced aggrecan breakdown in articular cartilage (C. Gendron, M. Kashiwagi and H. Nagase, unpublished work), suggesting that delivery or increased production of TIMP-3 in articular cartilage may protect against cartilage degradation that occurs in various types of arthritis.
To investigate the structural basis of the ability of TIMP-3 to inhibit aggrecanase, we have generated a series of chimaeric N-TIMPs by introducing different portions of TIMP-3 into TIMP-1 from the N-terminus. The chimaera consisting of N-TIMP-3-(1-68) and N-TIMP-1-(71-124) contains all the residues present in the reactive-site ridge of N-TIMP-3, but it does not inhibit ADAMTS-4. Nevertheless, this protein inhibits MMP-1, -2 and -3 with inhibition constants similar to those of wild-type N-TIMP-3, and it is therefore essentially a TIMP-3 rather than a TIMP-1. Replacement of the stretch of the sequence EASESL (residues 62-67) in TIMP-3 by PAMESV (residues 64-69) derived from TIMP-1 did not alter the activity of N-TIMP-3 as an inhibitor of ADAMTS-4 (M. Kashiwagi, O. Polyakova, K. Brew and H. Nagase, unpublished work). These results suggest that the MMP reactive ridge alone of TIMP-3 is not sufficient to inhibit ADAMTS-4, but that additional elements are required.
Conclusions and future prospects
The TIMPs are important regulators of ECM catabolism through their ability to control the activities of MMPs and some ADAM and ADAMTS metalloproteinases. Our mutational studies have provided us with TIMP variants that have selective inhibitory activity for particular MMPs. Although inhibitors that are specific for a single MMP have not yet been designed, the results obtained so far encourage future studies in this direction. Our studies also highlight the unique nature of the reactive-site ridge in TIMPs. The requirement for a hydrophobic side chain in the P1Ј position of peptide substrates of MMPs is well established, but this requirement does not correlate with that of the inhibitory TIMP molecule. P1Ј side chains that produce a poor substrate are often found to be excellent for inhibitory activity when substituted at the corresponding site (residue 2) in TIMP-1, and in this location significantly influence the inhibitory specificity. This feature of residue 2 and the influence of other residues in the reactive ridge on the affinity of TIMP for different metalloproteinases are worthy of investigation as a route to generating more selective inhibitors.
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TIMPs were originally discovered as MMP inhibitors, and are used as reagents to discriminate MMPs from metalloproteinases of other families, such as thermolysin, neprilysin and astacins. However, recent studies have shown that TIMP-3 can inhibit a number of ADAM and ADAMTS metalloproteinases. This finding is of considerable interest to many researchers, as these metalloproteinases play important roles in inflammatory processes, the shedding of cell surface molecules, and the degradation and processing of ECM molecules. The results of our initial mutational studies designed to elucidate possible unique elements for the inhibition of ADAMTS-4 were surprising, as complete replacement of the reactive-ridge region of TIMP-1 by that of TIMP-3 produced a molecule devoid of ADAMTS-4 inhibitory activity, indicating that additional key elements are present in TIMP-3. While the search for such features is under way, the structural basis for this inhibitory specificity requires the determination of the structure of TIMP-3.
Because MMPs are implicated in the progression of many diseases associated with aberrant ECM turnover, numerous synthetic MMP inhibitors have been designed and some have been clinically tested, but with little success [54] . The reasons for the failure of low-molecular-mass inhibitors are not clear, but it could result from the inhibition of non-targeted metalloproteinases or the fact that the disease had progressed to a point where it could not be reversed by the inhibition of MMPs. It is also possible that the inhibitor concentration in the target tissue did not reach an effective level. Animal model studies with selective TIMP variants that exploit tissue-specific gene transfer technology may be useful to investigate which MMPs, ADAMs and ADAMTSs are involved in disease progression. and to further develop therapeutic interventions for diseases linked with enhanced ECM degradation. To this end, and in order to design highly selective inhibitors, we need detailed structural information about the modes of interaction between various target metalloproteinases and TIMP variants.
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